Hepatitis E News and Research

RSS

Hepatitis E is a viral hepatitis (liver inflammation) caused by infection with a virus called hepatitis E virus (HEV).

Liver stiffness indicates severe portal hypertension in patients with hepatitis C-related cirrhosis

Measuring liver stiffness using transient elastography can predict severe portal hypertension in patients with hepatitis C-related cirrhosis, according to a new study in the May issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

2 May 2007

Cellular protein found that interferes with hepatitis C virus replication

Biomedical researchers have identified a cellular protein that interferes with hepatitis C virus replication, a finding that ultimately may help scientists develop new drugs to fight the virus.

30 Apr 2007

New test for liver disease

A researcher at the Stanford University School of Medicine has helped confirm the reliability of a new test for liver disease that is ushering in the long-promised era of personalized medicine based on each individual's genetic makeup.

30 Apr 2007

Liver center leading record number of studies to tackle hepatitis C

While many research institutions are suffering from funding cuts, Drs. Bruce R. Bacon and Adrian M. Di Bisceglie are chugging away with their usual tenacity.

27 Apr 2007

New study on prisoner health

People with chronic illnesses can experience great difficulties in prison, but people such as drug addicts and the homeless may find their healthcare improves, according to a study in the latest Journal of Advanced Nursing.

26 Apr 2007

Chronically ill prisoners can face great healthcare problems, but others inmates enjoy improved health

25 Apr 2007

Researchers identify key gene that may be a marker of breast cancer metastasis

Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common.

19 Apr 2007

Researchers find hepatitis A and hepatitis C attack same protein to block immune defenses

Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common.

19 Apr 2007

Vaccination week in the Americas

The countries of the Americas are preparing a huge promotional effort for the fifth year of Vaccination Week in the Americas, which this year aims to immunize some 55 million persons.

18 Apr 2007

Potential biomarkers for early detection of liver cancer

Researchers at Columbia University's Mailman School of Public Health have discovered a means for early detection of liver cancer.

16 Apr 2007

Human Genome Sciences reports results of phase 2b trial of Albuferon

Human Genome Sciences has reported results at Week 12 following the completion of therapy (SVR12) in a Phase 2b clinical trial of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens.

16 Apr 2007

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment.

16 Apr 2007

New drug therapy zaps hepatitis C in 12 weeks

Trials of new hepatitis C drug suggest sufferers could be cleared of the virus within 12 weeks of treatment.

16 Apr 2007

Use of computer-assisted drug design in drug discovery

Metabasis Therapeutics has announced that on March 27, 2007 at the American Chemical Society 233rd National Meeting and Exposition in Chicago, Dr. M. Rami Reddy presented, "Use of Computer-Assisted Drug Design in Drug Discovery: Limitations and Advantages of Available Computational Methods."

15 Apr 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007

CuraGen announces results with Belinostat and Velafermin

CuraGen Corporation has announced that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007.

15 Apr 2007

Scientists gain insights into liver regeneration

The way the liver renews itself may be simpler than what scientists had been assuming.

12 Apr 2007

Schering-Plough commits to chronic hepatitis C research

Schering-Plough has reaffirmed its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) infection with several key data presentations at the European Association for the Study of the Liver (EASL) 42nd annual meeting in Barcelona, Spain, April 11-15.

11 Apr 2007

Freedom from the egg holds much promise for new flu vaccines

An experimental flu vaccine made in insect cells – not in eggs, where flu vaccines currently available in the United States are grown – is safe and as effective as conventional vaccines in protecting people against the flu, according to results published in the April 11 issue of the Journal of the American Medical Association .

11 Apr 2007